Bicycle Therapeutics PLC Sponsored ADR (BCYC) closed the last trading session at $22.96, gaining 3.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $43.38 indicates an 88.9% upside potential.The mean estimate comprises eight short-term price targets with a standard deviation of $12.91. While the lowest estimate of $28 indicates a 22% increase from the current price level, the mos ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Ordinary shares, nominal value £0.01 per share* n/a The Nasdaq Stock Market LLC American Depositary Shares, each representing one ordinary share, nominal value £0.01 per share BCYC The Nasdaq Stock Market LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ...

Exhibit 99.1 Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results Four abstracts containing data updates across clinical pipeline accepted for poster presentation at ESMO Congress 2024 Focused R&D pipeline on clinical programs and research areas that have the highest potential to maximize value creation Streamlined leadership team to better align with strategic and pipeline priorities, and enhanced oncology expertise with formation of Clinical Advisory Board Streng ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Bicycle Therapeutics PLC Sponsored ADR (BCYC) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Bicycle Therapeutics PLC Sponsored ADR is one of 1040 companies in the Medical group. The Medical group currently sits at #7 within the Zacks Sector Rank. ...

Group 1 - Bicycle Therapeutics PLC Sponsored ADR (BCYC) has gained approximately 28.1% year-to-date, outperforming the average gain of 6.2% in the Medical sector [2] - The Zacks Consensus Estimate for BCYC's full-year earnings has increased by 14.6% over the past quarter, indicating improved analyst sentiment and a stronger earnings outlook [2] - BCYC is currently ranked 2 (Buy) in the Zacks Rank system, which emphasizes earnings estimates and revisions [1] Group 2 - Bicycle Therapeutics PLC is part of the Medical - Biomedical and Genetics industry, which has seen an average loss of 3.8% year-to-date, highlighting BCYC's superior performance [3] - Another outperforming stock in the Medical sector is Brookdale Senior Living (BKD), which has returned 14.6% year-to-date and is also ranked 2 (Buy) [2] - The Medical - Nursing Homes industry, to which Brookdale Senior Living belongs, is currently ranked 16 and has gained 7.5% year-to-date [3]

Core Viewpoint - Bicycle Therapeutics (BCYC) has entered into a funding agreement to issue 25,933,706 American Depositary Shares (ADS) at $21.42 per share, expected to generate approximately $555 million in gross proceeds, significantly strengthening its cash position and extending its financial runway into the second half of 2027 [1][2]. Group 1: Funding and Financial Position - The PIPE financing will close on May 28, 2024, contingent upon customary closing conditions [1]. - Post-transaction, the company anticipates its cash and cash equivalents to be around $1 billion, which is an estimate subject to change [2]. - Net proceeds from the PIPE funding will support ongoing development activities of its clinical-stage pipeline [2]. Group 2: Clinical Pipeline and Development - Bicycle Therapeutics' lead candidate, BT8009, is being evaluated in two clinical studies for different cancer indications, including metastatic bladder cancer [2][3]. - The company has aligned with the FDA on the design of the Duravelo-2 study, which may lead to accelerated approval for treating metastatic bladder cancer [3]. - The clinical-stage pipeline includes three other candidates: BT5528, BT1718, and BT7480, which are in various stages of development [3]. Group 3: Market Performance - Year to date, BCYC shares have increased by 29.9%, contrasting with a 6% decline in the industry [2].

Core Viewpoint - Bicycle Therapeutics PLC (BCYC) shows significant upside potential with a mean price target of $43.56, indicating an 85.5% increase from its current price of $23.48 [1] Price Targets and Analyst Consensus - The mean estimate consists of nine short-term price targets with a standard deviation of $11.61, suggesting variability in analyst predictions [1] - The lowest estimate of $30 indicates a 27.8% increase, while the highest estimate suggests a 155.5% surge to $60 [1] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement [4] Earnings Estimates and Revisions - Analysts have shown increasing optimism about BCYC's earnings prospects, with eight estimates revised higher in the last 30 days and no negative revisions [5] - The Zacks Consensus Estimate for the current year has increased by 14.6% due to these positive revisions [5] Zacks Rank and Investment Potential - BCYC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [6] - This rank, along with the positive earnings revisions, suggests a strong potential for upside in the near term [6]

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Bicycle Therapeutics PLC Sponsored ADR (BCYC) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.Bicycle Therapeutics PLC Sponsored ADR is a member of the Medical sector. This group includes 1047 individual stocks ...

Core Viewpoint - Bicycle Therapeutics PLC has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates which is a significant factor influencing stock prices [1][2]. Earnings Outlook - The Zacks rating upgrade reflects an improvement in the earnings outlook for Bicycle Therapeutics, which is expected to positively impact its stock price [2]. - The company is projected to earn -$5.13 per share for the fiscal year ending December 2024, showing a year-over-year change of -1% [5]. Earnings Estimate Revisions - Over the past three months, the Zacks Consensus Estimate for Bicycle Therapeutics has increased by 8.3%, indicating a positive trend in earnings estimates [5]. - The Zacks Rank system effectively utilizes earnings estimate revisions to classify stocks, with a strong correlation between these revisions and near-term stock movements [4]. Institutional Investor Influence - Institutional investors play a role in the relationship between earnings estimates and stock price movements, as they adjust their valuations based on changes in earnings estimates [3]. - The upgrade to Zacks Rank 2 places Bicycle Therapeutics in the top 20% of Zacks-covered stocks, suggesting potential for higher stock movement in the near term [7].

Shares of Bicycle Therapeutics PLC Sponsored ADR (BCYC) have gained 8.1% over the past four weeks to close the last trading session at $24.58, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $43.56 indicates a potential upside of 77.2%.The average comprises nine short-term price targets ranging from a low of $30 to a high of $60, with a standard deviation of $11.61. While the lo ...